FTC Approves Final Order Requiring Animal Health Product Suppliers Elanco Animal Health, Inc. and Bayer Animal Health GmbH to Divest Assets in Three Product Markets as a Condition of Acquisition

Following a public comment period, the Federal Trade Commission has approved a final ordersettling charges that animal health products supplier Elanco Animal Health, Inc.s proposed $7.6 billion acquisition of Bayer Animal Health, Inc. would likely be anticompetitive.

Metadata
Provider: 
FTCFTC
URL: 
https://www.ftc.gov/news-events/press-releases/2020/09/ftc-approves-final-order-requiring-animal-health-producthttps://www.ftc.gov/news-events/press-releases/2020/09/ftc-approves-final-order-requiring-animal-health-product
Retrieved on: 
Friday, September 11, 2020
Information
Tags: 
Companies, Health, Articles, Elanco, Neogen, Bayer, Nitenpyram, Otitis externa, Otitis, Divestment
Summary
Key Points: 
  • Following a public comment period, the Federal Trade Commission has approved a final ordersettling charges that animal health products supplier Elanco Animal Health, Inc.s proposed $7.6 billion acquisition of Bayer Animal Health, Inc. would likely be anticompetitive.
  • The final order requires Elanco to divest its canine otitis externa treatment, Osurnia, to Dechra Limited; its fast-acting oral treatment that kills adult fleas on dogs, Capstar, to PetIQ, LLC; and its brand name cattle pour-on insecticide, StandGuard, to Neogen Corporation.
  • Each divestiture requires Elanco to transfer all intellectual property and other related assets to the respective buyer.
  • The Commission vote to approve the final order was 4-0-1.
Copyright: 
2020 FTC. All Rights Reserved.